Blue light flexible cystoscopy with hexaminolevulinate in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on optimal use in the USA — update 2018

• Published in: Nature reviews. Urology 2019-06, Vol.16 (6), p.377-386
• Main Authors: Lotan, Yair, Bivalacqua, Trinity J., Downs, Tracy, Huang, William, Jones, Jeffrey, Kamat, Ashish M., Konety, Badrinath, Malmström, Per-Uno, McKiernan, James, O’Donnell, Michael, Patel, Sanjay, Pohar, Kamal, Resnick, Matthew, Sankin, Alexander, Smith, Angela, Steinberg, Gary, Trabulsi, Edouard, Woods, Michael, Daneshmand, Siamak
• Format: Article
• Language: English
• Subjects: 631/1647/245/164; 692/4028/67/2321; 692/699/67/589/1336; Aminolevulinic Acid - analogs & derivatives; Bladder cancer; Care and treatment; Consensus Development Conferences as Topic; Consensus Statement; Cystectomy - methods; Cystoscopes; Cystoscopy; Cystoscopy - methods; Development and progression; Diagnosis; Equipment Design; Humans; Light; Medicine; Medicine & Public Health; Neoplasm Invasiveness; Practice Guidelines as Topic; Surgery, Computer-Assisted; Surveillance; United States; Urinary Bladder Neoplasms - pathology; Urinary Bladder Neoplasms - surgery; Urology
• ISSN: 1759-4812; 1759-4820; 1759-4820
• DOI: 10.1038/s41585-019-0184-4

Blue light cystoscopy (BLC) with hexaminolevulinate (HAL) during transurethral resection of bladder cancer improves detection of non-muscle-invasive bladder cancer (NMIBC) and reduces recurrence rates. Flexible BLC was approved by the FDA in 2018 for use in the surveillance setting and was demonstrated to improve detection. Results of a phase III prospective multicentre study of blue light flexible cystoscopy (BLFC) in surveillance of intermediate-risk and high-risk NMIBC showed that 20.6% of malignancies were identified only by BLFC. Improved detection rates in the surveillance setting are anticipated to lead to improved clinical outcomes by reducing future recurrences and earlier identification of tumours that are unresponsive to therapy. Thus, BLFC has a role in surveillance cystoscopy, and determining which patients will benefit from BLFC and optimal and cost-effective ways of incorporating this technology into surveillance cystoscopy must be developed. In this Consensus Statement, experts in the field detail the current evidence regarding blue light flexible cystoscopy for bladder cancer surveillance and make recommendations regarding its use on the basis of conclusions arrived at during the panel discussions at a consensus meeting.